(Wilding JPH et al., NEJM 2021) STEP Trial Outcomes Relevant to Michigan Prescribers In STEP-1, 86.4% of semaglutide-treated participants lost at least 5% of body weight, and 69.1% lost at least 10%
Of course, in this instance, more is better
Consequently, although obesity affects hundreds of millions of people globally, GLP-1 therapies currently reach only a small fraction of eligible patients, underscoring the substantial unmet need for more convenient, scalable, and accessible treatment options
On flat-rate compounded GLP-1, NexLife is competitive or lower than Mochi Health on a 12-month cost basis
Cervical lymphadenopathy with cancer is uncommon
GLP-1 medications are generally well-tolerated with side effects primarily gastrointestinal and dose-dependent, often improving with continued use